Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.

Clinical pharmacology and therapeutics - 1 Nov 2022

Lee Craig R, Luzum Jasmine A, Sangkuhl Katrin, Gammal Roseann S, Sabatine Marc S, Stein Charles Michael, Kisor David F, Limdi Nita A, Lee Yee Ming, Scott Stuart A, Hulot Jean-Sébastien, Roden Dan M, Gaedigk Andrea, Caudle Kelly E, Klein Teri E, Johnson Julie A, Shuldiner Alan R

Abstract excerpt

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events. This guideline is an update to the 2013 Clinical Pharmacogenetics Implementation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenetics

Share to Platelet Aggregation Inhibitors

Share to Prodrugs

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 35034351
DOI: 10.1002/cpt.2526
PMCID: PMC9287492

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.PMID 35034351Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.Semantic proximity Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

Implementation of clopidogrel pharmacogenetics: a Brazilian perspective.Semantic proximity Read ↗

Clopidogrel PharmacogeneticsSemantic proximity Read ↗

2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping.Semantic proximity Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?Semantic proximity Read ↗

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.